Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse MKT  >  Protalix BioTherapeutics Inc.    PLX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
07/27/2015 07/28/2015 07/29/2015 07/30/2015 07/31/2015 Date
1.71(c) 1.67(c) 1.65(c) 1.59(c) 1.67 Last
115 228 157 782 134 749 152 309 41 117 Volume
0.00% -2.34% -1.20% -3.64% +5.03% Change
More quotes
Financials ($)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
PER 2013 -
PER 2014
Capi. / Sales 2013 9,45x
Capi. / Sales 2014 4,16x
Capitalization 149 M
More Financials
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system.It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.Its drug... 
More about the company
Surperformance© ratings of Protalix BioTherapeutics I
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTALIX BIOTHERAPEUTICS I
07/28 PROTALIX BIOTHERAPEUTICS : CollPlant Names Shomrat Shurtz Senior Director of Bus..
07/28 COLLPLANT : Names Shomrat Shurtz Senior Director of Business Development
06/12 Protalix BioTherapeutics Announces AIR DNase(TM) Data Presented at the 38th E..
05/14 Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences
05/08 PROTALIX BIOTHERAPEUTICS : Reports First Quarter 2015 Financial Results
05/07 PROTALIX BIOTHERAPEUTICS : Results of Operations and Financial Condition (form 8..
05/07 Protalix BioTherapeutics Reports First Quarter 2015 Financial Results
03/13 PROTALIX BIOTHERAPEUTICS : Reports Full Year 2014 Financial Results and Provides..
More news
Sector news : Biotechnology & Medical Research - NEC
08:02a QUINTILES TRANSNATIONAL : Announces Pricing of Secondary Public Offering
07/30 SEATTLE GENETICS : reports 2Q loss
07/30 QUINTILES TRANSNATIONAL : Announces Launch of Secondary Public Offering of Commo..
More sector news : Biotechnology & Medical Research - NEC
Comments 
Advertisement
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix BioTherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions